NervGen Pharma (NGENF) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free NGENF Stock Alerts $1.50 -0.03 (-1.96%) (As of 04/25/2024 05:19 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNervGen Pharma Corp. (NGENF)finance.yahoo.com - April 20 at 7:45 PMNervGen Pharma Reports 2023 Year-End Financial Results and Operational Updatesfinance.yahoo.com - April 17 at 10:41 AMNervGen Completes $23 Million Bought Deal Financingfinance.yahoo.com - March 28 at 7:38 PMCanadian Investment Regulatory Organization Trade Resumption - NGENfinance.yahoo.com - March 22 at 8:46 PMNERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERINGfinance.yahoo.com - March 21 at 7:06 PMNervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injuryfinance.yahoo.com - February 15 at 12:41 PMNervGen Pharma GAAP EPS of -$0.07msn.com - November 9 at 12:19 PMNeuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasakifinance.yahoo.com - November 8 at 12:48 PMNervGen Pharma Corp Ordinary Shares NGENFmorningstar.com - November 4 at 6:59 PMNervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injuryfinance.yahoo.com - September 25 at 9:13 AMNervGen Pharma to Present at 2023 International Spinal Research Trust Network Meetingfinance.yahoo.com - September 11 at 11:39 AMNervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 5 at 5:11 PMNervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conferencefinance.yahoo.com - August 22 at 9:08 AMNervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approvalfinance.yahoo.com - August 8 at 10:15 AMNervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injuryfinance.yahoo.com - June 27 at 9:31 AMNervGen Pharma to Present at Upcoming Investor Conferencesfinance.yahoo.com - June 20 at 8:42 PMNervGen Pharma Corp.: NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291finanznachrichten.de - May 15 at 8:48 AMNervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291finance.yahoo.com - May 15 at 8:48 AMRaleigh/Durham Pharmaceuticals Newsbizjournals.com - April 14 at 6:33 PMNervGen Pharma Appoints Michael Kelly as President & Chief Executive Officerfinance.yahoo.com - April 10 at 9:11 AMNervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023finance.yahoo.com - March 30 at 11:50 AMNervGen Pharma Corp. (NGEN.V)ca.finance.yahoo.com - March 22 at 8:44 AMNervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291finance.yahoo.com - February 14 at 8:30 AMNGEN:CA NervGen Pharma Corp.seekingalpha.com - January 31 at 6:06 PMNervGen Pharma Stock (OTC:NGENF), Quotes and News Summarybenzinga.com - January 10 at 11:41 PMNervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Officefinance.yahoo.com - November 17 at 11:03 AMNervGen Pharma Completes Dosing in Its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Resultsfinance.yahoo.com - November 14 at 11:06 AMNervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291finance.yahoo.com - October 25 at 9:49 AMNervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Developmentfinance.yahoo.com - September 12 at 9:27 AMHas The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?finance.yahoo.com - September 8 at 5:33 PMNervGen Pharma Presenting at Upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meetingfinance.yahoo.com - September 8 at 12:31 PMNervGen Pharma (NGENF) Investor Presentation - Slideshowseekingalpha.com - August 14 at 6:51 PMNervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 1:58 PMNervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conferencefinance.yahoo.com - August 2 at 1:10 PMNervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve Universityfinance.yahoo.com - July 28 at 12:39 PMNervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directorsfinance.yahoo.com - July 14 at 10:58 AMNervGen Pharma Provides Update on Closing of Private Placementfinance.yahoo.com - July 11 at 1:13 PMNervGen Pharma (OTC:NGENF), Short Interest Reportbenzinga.com - July 7 at 10:18 PMNervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placementfinance.yahoo.com - June 30 at 7:34 PMNervGen Pharma Corp.: NervGen Pharma Grants Stock Optionsfinanznachrichten.de - June 2 at 9:23 PMNERVGEN PHARMA CORPfinanznachrichten.de - May 25 at 5:16 AMNervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)finance.yahoo.com - May 16 at 10:39 AMNervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Resultsfinance.yahoo.com - May 12 at 9:18 AMNervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meetingfinance.yahoo.com - March 31 at 10:05 AMNervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Groupfinance.yahoo.com - March 23 at 9:26 AMNervGen Pharma gets safety panel nod to advance in phase 1 trial of NVG-291seekingalpha.com - March 15 at 5:44 PMNervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291finance.yahoo.com - March 15 at 12:43 PMWe're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Ratefinance.yahoo.com - March 3 at 7:06 PMNervGen Pharma Corp.: NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Studyfinanznachrichten.de - March 1 at 11:13 PMNervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine & Rehabilitationfinance.yahoo.com - January 10 at 8:10 AM Get NervGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NGENF and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). NGENF Media Mentions By Week NGENF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NGENF News Sentiment▼0.000.41▲Average Medical News Sentiment NGENF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NGENF Articles This Week▼20▲NGENF Articles Average Week Get NervGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NGENF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KNTE News Today NGM News Today CYBN News Today LIAN News Today ORMP News Today MCRB News Today IOBT News Today DMAC News Today ABEO News Today BLUA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:NGENF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
